| 郭应丽,阿怀红,廖东升,赵成玉,韩春娜.帕利哌酮治疗伴有精神病性症状的抑郁发作患者的疗效分析及对神经功能及血清BDNF的影响[J].,2022,(11):2171-2175 |
| 帕利哌酮治疗伴有精神病性症状的抑郁发作患者的疗效分析及对神经功能及血清BDNF的影响 |
| Effect Analysis of Paraliperidone in Depressed Episode Patients with Psychotic Symptoms and Its Effects on Neurological Function and Serum BDNF |
| 投稿时间：2021-12-06 修订日期：2021-12-28 |
| DOI：10.13241/j.cnki.pmb.2022.11.034 |
| 中文关键词: 帕利哌酮 精神病性症状 抑郁发作 神经功能 血清BDNF |
| 英文关键词: Paliperidone Psychotic symptoms Depressive episodes Efficacy analysis Serum BDNF |
| 基金项目:青海省科技厅基础研究项目（2016-ZJ-718） |
|
| 摘要点击次数: 629 |
| 全文下载次数: 382 |
| 中文摘要: |
| 摘要 目的：探讨帕利哌酮治疗伴有精神病性症状的抑郁发作患者的疗效分析及对神经功能及血清脑源性神经营养因子（BDNF）的影响。方法：选取本院2021年1月到2021年10月收治的100例伴有精神病性症状的抑郁发作患者作为研究对象，随机将其分为观察组（n=50）和对照组（n=50）。对照组采用常规药物为伴有精神病性症状的抑郁发作患者进行治疗，观察组在对照组的基础上采用帕利哌酮为伴有精神病性症状的抑郁发作患者进行治疗，对比两组患者治疗前、治疗后2周、治疗后6周的汉密尔顿焦虑量表（HAMD）评分、汉密尔顿抑郁量表（HAMA）评分、精神经功能缺损程度、血清BDNE、神经病评定量表（BPRS）评分、社会功能缺陷筛选量表（SDSS）评分、日常生活能力量表（ADL）评分以及不良反应发生率。结果：治疗前两组患者的HAMA评分和HAMD评分对比无明显差异（P>0.05），治疗后2周、6周评分均降低，且观察组较对照组低（P＜0.05）；治疗前两组患者的NIHSS评分和血清BDNE水平对比无明显差异（P>0.05），治疗后2周、6周两组患者的NIHSS评分均低，且相较于观察组，对照组较高（P＜0.05），但血清BDNE水平均升高，且观察组较对照组高（P＜0.05）；治疗前两组患者的BPRS、SDSS、ADL评分对比明显差异（P＞0.05）。治疗后2周、6周两组患者的BPRS、SDSS皆降低，并且观察组低于对照组（P＜0.05），但两组患者的ADL评分均升高并且观察组高于对照组（P＜0.05）；观察组患者的不良反应总发生率与对照组比较无差异（P>0.05）。结论：将帕利哌酮应用于伴有精神病性症状的抑郁发作患者当中，可改善患者的焦虑、抑郁以及神经功能缺损情况，提高血清BDNE水平，并降低神经病性和社会功能缺陷情况，提高患者日常生活能力，值得临床借鉴。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of paliperidone in the treatment of patients with depressive episodes with psychotic symptoms and its effect on neurological function and serum BDNF. Methods: Select 100 patients with depressive episodes with psychotic symptoms admitted in our hospital from January 2021 to October 2021 as the research objects, and randomly divide them into study group (n=50) and control group (n=50). The control group was treated with conventional drugs and depressive episode patients with psychotic symptoms, and the study group was treated with paliperidone and depressive episode patients with psychotic symptoms on the basis of the control group. Compared two groups of patients before and after treatment for 2 weeks, 6 weeks after treatment the Hamilton anxiety scale(HAMD) scores, Hamilton depression scale(HAMA) score, mental function defect degree, serum BDNE, mental derangement rating scale (BPRS) scores, social function defect SDSS score, daily life ability scale (ADL) and the incidence of adverse reactions. Results: There was no difference between the HAMA score and HAMD score of the two groups of patients before treatment (P>0.05). The HAMA score and HAMD score of the two groups of patients decreased at 2 weeks and 6 weeks after treatment, and the study group was lower than the control Group(P<0.05); the comparison of NIHSS score and serum BDNE level of the two groups of patients before treatment had no difference(P>0.05), the NIHSS scores of the two groups of patients were reduced 2 weeks after treatment and 6 weeks after treatment, and the study group Lower than the control group(P<0.05), the serum BDNE levels of the two groups increased, and the study group was higher than the control group(P<0.05); the BPRS of the two groups before treatment The scores of, SDSS and ADL were not different(P>0.05). The BPRS and SDSS of the two groups of patients were decreased 2 weeks after treatment and 6 weeks after treatment, and the study group was lower than that of the control group(P<0.05), and the ADL scores of the two groups of patients increased, and the study group was higher than that of the control group(P<0.05); There was no difference in the total incidence of adverse reactions between study group and control group(P>0.05). Conclusion: Applying paliperidone to patients with depressive episodes with psychotic symptoms can improve patients' anxiety, depression and neurological deficits, increase serum BDNE levels, and reduce patients' neurological and social deficits. The daily life ability of patients is worthy of clinical promotion and application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
